"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Descriptor ID |
D016898
|
MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 8 | 6 | 14 |
1995 | 16 | 11 | 27 |
1996 | 6 | 8 | 14 |
1997 | 5 | 8 | 13 |
1998 | 15 | 8 | 23 |
1999 | 12 | 10 | 22 |
2000 | 11 | 6 | 17 |
2001 | 12 | 6 | 18 |
2002 | 12 | 5 | 17 |
2003 | 17 | 18 | 35 |
2004 | 19 | 9 | 28 |
2005 | 12 | 11 | 23 |
2006 | 8 | 9 | 17 |
2007 | 19 | 10 | 29 |
2008 | 10 | 9 | 19 |
2009 | 13 | 5 | 18 |
2010 | 10 | 9 | 19 |
2011 | 13 | 17 | 30 |
2012 | 10 | 5 | 15 |
2013 | 14 | 3 | 17 |
2014 | 10 | 7 | 17 |
2015 | 8 | 1 | 9 |
2016 | 6 | 1 | 7 |
2017 | 10 | 5 | 15 |
2018 | 4 | 5 | 9 |
2019 | 4 | 3 | 7 |
2020 | 4 | 2 | 6 |
2021 | 1 | 3 | 4 |
2022 | 0 | 3 | 3 |
2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. Front Immunol. 2023; 14:1260498.
-
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ~40% of patients. J Exp Med. 2023 09 04; 220(9).
-
Adenoviral gene therapy for bladder cancer. Cell. 2023 03 02; 186(5):893.
-
Long term study of topical interferon a-2b eye drops as primary treatment of ocular surface squamous neoplasia. Ocul Surf. 2023 04; 28:108-114.
-
Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency. J Infect Dis. 2022 Nov 11; 226(10):1781-1789.
-
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv. 2022 10 11; 6(19):5546-5549.
-
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat Biomed Eng. 2022 08; 6(8):992-1003.
-
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
-
An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2022 02; 63(2):315-325.